Arca
Skip to content
Tools
Tools

Lung disease

Drug research and approvals for lung disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 4,454 studies of lung disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 35 drug trials for it since 2013, and FDA has 3 approved and 6 open orphan designations naming it.

  • Recruiting worldwide: 4,454
  • Trials authorized in Canada: 35
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 4,454 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 12 of 21

Phase 2 12 of 24

Phase 1 or earlier 3

How its trials ended

3,504 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 830 whose ending is known, 55% met their primary endpoint, 10% missed it and 35% stopped early.

  • Completed, result not reported1,61946%
  • Ongoing58017%
  • Status unknown47514%
  • Met its primary endpoint45813%
  • Stopped: other or unclear1665%
  • Missed its primary endpoint852%
  • Stopped: enrollment or feasibility602%
  • Stopped: sponsor or business decision271%
  • Stopped: lack of efficacy241%
  • Stopped: funding9<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 35; search them all in Canada trials
Aug 31, 2026Imaging measures of respiratory health registryHyperpolarized XENON-129 / Perfluoropropane / OxygenThe Hospital for Sick ChildrenPending
Jun 17, 2026A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing…Nerandomilast (bi 1015550)Boehringer Ingelheim (Canada) Ltd LteeOngoing
May 7, 2026A phase 1/2, open-label, multi-center, dose escalation, dose expansion, and single repeat dose study of TSRA-196 in adults with the pizz genotype who have lung…TSRA-196Tessera Therapeutics, Inc.Pending
Apr 8, 2026A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age…Nerandomilast (bi 1015550)Boehringer Ingelheim (Canada) Ltd LteePending
Jan 20, 2026A phase 3, multicenter, randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy of L606 (treprostinil liposome inhalation…L606 (treprostinil)Liquidia TechnologiesOngoing
Sep 23, 2025A phase 2a, open-label, single arm multicenter exploratory study to evaluate the safety, tolerability, and efficacy of oral doses of ROC-101 in patients with…ROC-101Allrock Bio, Inc.Ongoing
Aug 20, 2025An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ILD) associated with systemic…BenlystaGSKPending
Jul 23, 2024Conquest platform clinical study for conquering scleroderma: a multicenter, double-blind, randomized, placebo-controlled, phase 2b platform clinical study to…Nerandomilast (bi 1015550)/ Amlitelimab (SAR445229)Scleroderma Research Foundation, Inc.Closed
Jul 17, 2024A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in…BelimumabGSKOngoing
Jun 26, 2024An open-label extension study of inhaled treprostinil in subjects with fibrotic lung diseaseTreprostinilUnited TherapeuticsOngoing

FDA orphan designations

Approved first, then open designations, newest first
Mar 4, 2021ActemraSlowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung diseaseGenentech, Inc.Approved
Sep 6, 2019OfevOFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung…Boehringer Ingelheim Pharmaceuticals, Inc.Approved
Sep 28, 2018ArikayceTreatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not…Insmed IncorporatedApproved
Mar 11, 2020PirfenidoneTreatment of Unclassifiable-interstitial lung diseaseLegacy Pharma Inc.Designated
Jun 5, 2018Nitric oxideTreatment of non-tuberculous mycobacterial lung diseaseNovoteris, LLCDesignated
Nov 19, 2013PirfenidoneTreatment of systemic sclerosis (including the associated interstitial lung disease)Legacy Pharma Inc.Designated
Sep 27, 2004Nitric oxideTo reduce the risk of chronic lung disease in premature neonatesKeenova Therapeutics Ireland LimitedDesignated
Feb 21, 2001PyruvateTreatment of interstitial lung disease.Cellular Sciences, IncDesignated
Jun 4, 1996Selective inhibitor of polymorphonuclear leukocyte (PMN)…Therapeutic management of patients with lung disease attributable to cystic fibrosis.DuPont Pharmaceuticals CompanyDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.